Trial · NCT02197455
Tofacitnib for the Treatment of Alopecia Areata and Variants
NCT02197455, Phase 2, Completed, Yale University; results first posted 2017-04-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tofacitnib for the Treatment of Alopecia Areata and Variants. Trials, record NCT02197455. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02197455
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tofacitnib for the Treatment of Alopecia Areata and Variants
- NCT number
- NCT02197455
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)
- Interventions
- Tofacitinib Administration
- First posted
- 2014-07-22
- Last updated
- 2017-04-04
- Results first posted
- 2017-04-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change in Severity of Alopecia Tool (SALT) Score | 3 months | SALT score range is from 0 (no hair loss) to 100 (100% hair loss) |
| Secondary | Mean Change in Skindex 16 Scores | 3 months | Skindex 16 is a quality of life questionaire with a range of 0-100 wherein 1 is not bothered by the condition and 100 is always bothered by the condition |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change in Severity of Alopecia Tool (SALT) Score | 3 months | percent change in SALT score | MEAN | |
| SECONDARY | Mean Change in Skindex 16 Scores | 3 months | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in Severity of Alopecia Tool (SALT) Score | Tofacitinib Administration | 22.8 | Standard Deviation 30.3 | percent change in SALT score | |
| Mean Change in Skindex 16 Scores | Tofacitinib Administration | -20.3 | Full Range -61.6 to 7.3 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tofacitinib Administration | 30 | |
| Overall Study | COMPLETED | Tofacitinib Administration | 30 | |
| Overall Study | NOT COMPLETED | Tofacitinib Administration | 0 |
Source ClinicalTrials.gov
Adverse events7
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | cold | Infections and infestations | Tofacitinib Administration | 3 | 30 | |
| other | sinus infection | Infections and infestations | Tofacitinib Administration | 2 | 30 | |
| other | headache | Nervous system disorders | Tofacitinib Administration | 3 | 30 | |
| other | abdominal pain | Gastrointestinal disorders | Tofacitinib Administration | 2 | 30 | |
| other | acne | Skin and subcutaneous tissue disorders | Tofacitinib Administration | 4 | 30 | |
| other | fatigue | General disorders | Tofacitinib Administration | 2 | 30 | |
| other | night sweats | Skin and subcutaneous tissue disorders | Tofacitinib Administration | 2 | 30 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tofacitinib Administration | ||
| Total, other adverse events | Tofacitinib Administration | 18 | 30 |
| Total, serious adverse events | Tofacitinib Administration | 0 | 30 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27699252 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02197455
GET https://conductscience.org/api/trials/v1/NCT02197455/registered